Bibliografías temáticas / DRUG DESIGNING / Libros

Libros sobre el tema "DRUG DESIGNING"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: DRUG DESIGNING.
Autor: Grafiati
Publicado: 11 de septiembre de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores mejores libros para su investigación sobre el tema "DRUG DESIGNING".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore libros sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Kinam, Park y Mrsny Randy J. 1955-, eds. Controlled drug delivery: Designing technologies for the future. Washington, D.C: American Chemical Society, 2000.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Evans, David G. Designing an effective drug-free workplace compliance program. Deerfield, IL: Clark Boardman Callaghan, 1993.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Mayforth, Ruth D. Designing antibodies. San Diego: Academic Press, Inc., 1993.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

R, Antos Joseph, Spoor Christian y United States. Congressional Budget Office., eds. Issues in designing a prescription drug benefit for Medicare. [Washington, D.C.]: Congress of the United States, Congressional Budget Office, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

1942-, Ellickson Phyllis L., ed. Designing and implementing Project ALERT: A smoking and drug prevention experiment. Santa Monica, CA: RAND, 1988.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Loomis, Lloyd. Drug testing: A workplace guide to designing practical policies and winning arbitrations. Washington, D.C: Bureau of National Affairs, 1990.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Center, Joslin Diabetes, ed. Joslin's insulin deskbook: Designing and initiating insulin treatment programs. Boston, MA: Joslin Diabetes Center, c2008., 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Rahrer, J. Stuart. Preparing for tomorrow-- today: Designing a personalized plan to prevent your child's alcohol-drug abuse. Fort Wayne, IN: Pharos Consulting & Publications, 1997.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Barbara, Davis. Peer support: Designing interpersonal skills training plan. [Edmonton]: Alberta Alcohol and Drug Abuse Commission, 1989.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

March, Darren. Designing new antiviral drugs for AIDS: HIV-1 protease and its inhibitors. Austin: R.G. Landes, 1996.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Morphy, J. Richard y C. John Harris, eds. Designing Multi-Target Drugs. Cambridge: Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849734912.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Designing a twenty-first century Medicare prescription drug benefit: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, first session, April 8, 2003. Washington: U.S. G.P.O., 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

1936-, Martin Yvonne Connolly y Willett Peter 1953-, eds. Designing bioactive molecules: Three-dimensional techniques and applications. Washington, DC: American Chemical Society, 1998.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

1964-, Kimko Hui C. y Duffull Stephen B. 1964-, eds. Simulation for designing clinical trials: A pharmacokinetic-pharmacodynamic modeling perspective. New York: Marcel Dekker, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Barger, Raymond L. A method for designing blended wing-body configurations for low wave drag. [Washington, DC]: National Aeronautics and Space Administration, Office of Management, Scientific and Technical Information Program, 1992.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Dashora, Kamlesh. Drug Designing. Discovery Publishing House Pvt Ltd, 2016.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Kothekar, V. Essentials of Drug Designing. Dhruv Publications, 2005.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Designing Multi-Target Drugs. Royal Society of Chemistry, The, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Designing Hydrogels for Controlled Drug Delivery. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03928-357-6.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Sharma, Anju, Rajnish Kumar y Rajesh Kumar Tiwari. Introduction to Drug Designing and Development. Nova Science Publishers, Incorporated, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

Mani, Ashutosh. Recent Advances in Computer Aided Drug Designing. Nova Science Publishers, Incorporated, 2021.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Mani, Ashutosh. Recent Advances in Computer Aided Drug Designing. Nova Science Publishers, Incorporated, 2021.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Gupta, Sikha. Insilico Screning & Drug Designing For Lipoic Acid-B Protein. LAP Lambert Academic Publishing, 2012.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Antos, Joseph. Issues in Designing a Prescription Drug Benefit for Medicare. Diane Pub Co, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

(Editor), Kinam Park y Randall J. Mrsny (Editor), eds. Controlled Drug Delivery: Designing Technologies for the Future (Acs Symposium Series). An American Chemical Society Publication, 2000.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Jojarth, Christine. Crime, War, and Global Trafficking: Designing International Cooperation. Cambridge University Press, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

A Practical Guide To Designing Phase Ii Trials In Oncology. John Wiley & Sons Inc, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Designing Alcohol and Other Drug Prevention Programs in higher education: Bringing theory into practice. Newton, Mass: U.S. Dept. of Education, Office of Educational Research and Improvement, Educational Resources Information Center, 1997.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

O'Quigley, John, Alexia Iasonos y Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

O'Quigley, John, Alexia Iasonos y Björn Bornkamp. Handbook of Methods for Designing Monitoring and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2019.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

O'Quigley, John, Alexia Iasonos y Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

O'Quigley, John, Alexia Iasonos y Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

Bilirakis, Michael. Designing a Twenty-first Century Medicare Prescription Drug Benefit: Hearing Before the Comm. on Energy And Commerce, U.s. House of Representatives. Diane Pub Co, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

US GOVERNMENT. Designing a Twenty-First Century Medicare Prescription Drug Benefit: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce. Government Printing Office, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

National Aeronautics and Space Administration (NASA) Staff. Method for Designing Blended Wing-Body Configurations for Low Wave Drag. Independently Published, 2018.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

(Editor), M. G. Ford y European Symposium on Quantitative Structure-Activity Relationships 20 (Editor), eds. Euroqsar 2002 Designing Drugs and Crop Protectants: Processes, Problems and Solutions. Blackwell Publishers, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

O'Quigley, John, Alexia Iasonos y Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Designing Bioactive Molecules: Three-Dimensional Techniques and Applications (Computer Applications in Chemistry Collection). An American Chemical Society Publication, 1998.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Sjøgren, Per, Frank Elsner y Stein Kaasa. Non-opioid analgesics. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0096.

Texto completo
Resumen
Non-opioid analgesics encompass the non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen). The NSAIDs include acetylsalicylic acid (ASA, aspirin), dipyrone (metamizole), and numerous other drugs in diverse classes. The NSAIDs have potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. In palliative medicine, they represent the first step of the World Health Organization’s analgesic ladder used for mild pain and they are an important supplement to opioids and adjuvant drugs at higher steps of the ladder. The disadvantages of non-opioid analgesics include a ceiling effect for pain relief and the risk of side effects. NSAIDs are also associated with an increased risk of adverse gastrointestinal, renal, and cardiovascular effects and hepatotoxicity can result from overdosing with paracetamol. This chapter describes the clinical pharmacology of NSAIDs, their classification, molecular mechanisms of action and adverse effects, as well as some recent developments aimed at designing effective anti-inflammatory agents with improved safety and tolerability profiles.
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Ray, Sumantra (Shumone), Sue Fitzpatrick, Rajna Golubic, Susan Fisher y Sarah Gibbings, eds. Clinical trial design. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199608478.003.0014.

Texto completo
Resumen
This chapter outlines the various study designs and their uses. The phases of drug development are described and the appropriate study design employed at each phase of development is identified Elimination of bias is critical to the study design and methods of eliminating bias are discussed, defining the population, randomisation and blinding. A summary of the elements to be considered when designing a study are presented including the types of control, placebo or active, and their uses, Non comparative and comparative designs are presented. In the comparative design both within and between patient designs are discussed including crossover, parallel, sequential, factorial and left right comparisons. Patient outcomes measures as well as efficacy measurement are required for new treatments. There is a brief review of pharmaeconomic study designs. Other types of study design, dose escalation and dose response studies are also discussed. As well as reducing bias in studies another critical element is the recording of the primary assessment methods. The choice of methods will affect other aspects of the study such as the statistical considerations. The methodology must be standardised and validated.
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Wohlbier, Thomas. Nanohybrids. Materials Research Forum LLC, 2021. http://dx.doi.org/10.21741/9781644901076.

Texto completo
Resumen
The book covers preparation, designing and utilization of nanohybrid materials for biomedical applications. These materials can improve the effectiveness of drugs, promote high cell growth in new scaffolds, and lead to biodegradable surgical sutures. The use of hybrid magneto-plasmonic nanoparticles may lead to non-invasive therapies. The most promising materials are based on silica nanostructures, polymers, bioresorbable metals, liposomes, biopolymeric electrospun nanofibers, graphene, and gelatin. Much research focuses on the development of biomaterials for cell regeneration and wound healing applications.
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective (Drugs and the Pharmaceutical Sciences, Vol 127) (Drugs and the Pharmaceutical Sciences). Informa Healthcare, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

Mills, Gary H. Under-representation of older people in clinical trials. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689644.003.0016.

Texto completo
Resumen
Key points• Older people, often with high levels of co-morbidity and polypharmacy, are increasing in number as the population ages.• Study populations in clinical trials have often not mirrored the population that will consume the drugs or treatments being investigated.• Regulators, ethics committees, and funding bodies must recognize the need for inclusion of older people and the complexities this imposes on investigators.• Across all aspects of medicine, funding for research into how best to safely include older people in clinical trials is vital.• Researchers should not be disadvantaged by designing studies to meet the needs of the age range of patients expected to receive the treatment being investigated; this should include provision for older people.
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Grant, Robert. Tumours of the brain and skull. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569381.003.0624.

Texto completo
Resumen
Over the last 10 years, there have been several important advances in cell biology, molecular genetics, and targeted therapies in neuro-oncology. Improved neurosurgical techniques such as frameless stereotaxy, awake craniotomy, and intra-operative MRI, safer methods of directing radiotherapy, new chemotherapy approaches, and novel modalities of therapy provide optimism that there will eventually be some improvements in treatment-related morbidity and survival. There has also been an increasing change from individual clinician decision making to decision making by multidisciplinary teams of neurosurgeons, neurologists, clinical oncologists, neuropathologists, neuroradiologists, and specialist nurses with the aim of improving decision making, management planning across specialties, communication, and enrolment in suitable clinical trials. In addition, Good Clinical Practice guidelines, an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials, increases the onus and responsibilities on clinical investigators to perform trials to the highest standard and to have the trials externally monitored, and the trial conduct and results audited. While these obligatory and statutory responsibilities are labour intensive and time consuming, they should improve the quality of trials by limiting the possibility of unintentional bias or fraud. Improving the recording of serious adverse event reporting through trial quality assurance and quality control procedures will help ensure that a balanced view of the effects of a drug or procedure is identified earlier than in the past. It will be interesting to see how research develops over the next decade.
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Knaggs, Roger D. The molecular structure of the μ‎-opioid receptor. Editado por Paul Farquhar-Smith, Pierre Beaulieu y Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0038.

Texto completo
Resumen
The landmark paper discussed in this chapter describes the crystal structure of the μ‎-opioid receptor (also known as MOP-1). Opioids are some of the oldest known drugs and have been used for over 4,000 years; however, in addition to having beneficial analgesic effects, they are associated with a myriad of side effects that can minimize their use. Although the gene sequences of the opioid receptors were determined in the 1990s it has taken much longer to translate this into visualizing their three-dimensional structure. The μ‎-opioid receptor consists of seven transmembrane α‎-helices that are connected by three extracellular loops and three intracellular loops, with a wide open binding pocket which offers many potential ligand interaction sites, and evidence of dimerization. Understanding the crystal structure of the μ‎-opioid receptor in much more detail aids explanation of the molecular determinants of ligand recognition and selectivity and will be of use in designing novel opioids with improved efficacy and fewer side effects.
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías sobre el tema "DRUG DESIGNING" para otros tipos de fuentes:
Artículos de revistas Tesis
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía